Rural and socioeconomic differences in the effectiveness of the HEART Pathway accelerated diagnostic protocol.

"CONFLICT OF INTEREST The authors declare no potential conflict of interest."

"FUNDING INFORMATION This project was funded by the Donaghue Foundation and the Association of American Medical Colleges (AAMC). Dr. O'Neill receives funding from Cytovale. Dr. Ashburn receives funding from NHLBI (T32HL076132). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Snavely receives funding from Abbott Laboratories and HRSA (1H2ARH399760100). Dr. Stopyra receives research funding from NCATS/NIH (KL2TR001421), HRSA (H2ARH39976‐01‐00), Roche Diagnostics, Abbott Laboratories, Pathfast, Genetesis, Cytovale, Forest Devices, Vifor Pharma, and Chiesi Farmaceutici. Dr. Mahler receives funding/support from Roche Diagnostics, Abbott Laboratories, Ortho Clinical Diagnostics, Siemens, Grifols, Pathfast, Quidel, Genetesis, Cytovale, and HRSA (1H2ARH399760100). He is a consultant for Roche, Quidel, Genetesis, Inflammatix, Radiometer, and Amgen and the chief medical officer for Impathiq Inc."

"This study was a preplanned secondary analysis of the HEART Pathway Implementation Study. Participants were recruited from November 2013 to January 2016 after approval by the Wake Forest University Health Sciences Institutional Review Board. The trial was registered with clincaltrials.gov (NCT02056964). The HEART Pathway Implementation Study's methods have been previously described. This article follows the Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) guidelines. "